AKTOVEGIN

Active material: deproteinized calves blood gemoderivat
When ATH: B06AB
CCF: Preparation, activates metabolism in tissues, improves trophic and stimulating the regeneration process
ICD-10 codes (testimony): F01, G45, I63, I73.0, I73.1, I73.9, I79.2, I83.2, L58, L89, S06, T14.1, T30, T90
When CSF: 02.14.07
Manufacturer: NYCOMED AUSTRIA GmbH (Austria)

Pharmaceutical form, composition and packaging

Solution for injection clear, yellowish, virtually particle-free.

Excipients: sodium chloride, water d / and.

2 ml – colorless glass vials (5) – packings Valium planimetric (1) – packs cardboard.
2 ml – colorless glass vials (5) – packings Valium planimetric (5) – packs cardboard.

Solution for injection clear, yellowish, virtually particle-free.

Excipients: sodium chloride, water d / and.

5 ml – colorless glass vials (5) – packings Valium planimetric (1) – packs cardboard.
5 ml – colorless glass vials (5) – packings Valium planimetric (5) – packs cardboard.

Solution for injection clear, yellowish, virtually particle-free.

Excipients: sodium chloride, water d / and.

10 ml – colorless glass vials (5) – packings Valium planimetric (1) – packs cardboard.
10 ml – colorless glass vials (5) – packings Valium planimetric (5) – packs cardboard.

Solution for infusion (in a solution of sodium chloride 0.9%) clear, colorless to slightly yellow.

Excipients: sodium chloride, water d / and.

250 ml – colorless glass vials (1) – packs cardboard.

Solution for infusion (in a solution of sodium chloride 0.9%) clear, colorless to slightly yellow.

Excipients: sodium chloride, water d / and.

250 ml – colorless glass vials (1) – packs cardboard.

Pharmacological action

Preparation, activates metabolism in tissues, reduces tissue hypoxia, improves trophic and stimulating the regeneration process. It represents gemoderivat, which is prepared by dialysis and ultrafiltration (penetrate compound with a molecular weight of less than 5000 Dalton).

Positive effect on the transport and utilization of glucose, stimulated oxygen consumption (which leads to stabilization of the plasma membranes of cells during ischemia and reduce lactate) having, thus, antihypoxic action.

Aktovegin^® increases the concentration of ATP, ADF, phosphocreatine, and amino acids (Glutamate, aspartate) and GABA.

Effect Actovegin^® It begins to occur no later than, than 30 m (10-30 m) after parenteral administration and reach peak, average, through 3 no (2-6 no).

Pharmacokinetics

With the help of pharmacokinetic methods is impossible to study the pharmacokinetic characteristics (absorption, distribution, deduction) the active ingredients of the drug Aktovegin^®, because it consists only of physiological components, which is normally present in the body.

Hitherto has been detected reduction gemoderivat pharmacological efficacy in patients with altered pharmacokinetics (incl. hepatic or renal insufficiency, changes in metabolism, associated with old age, due to the nature of metabolism in infants).

Testimony

- Metabolic and vascular disorders of the brain (incl. ischemic stroke, traumatic brain injury);

- Peripheral (arterial and venous) vascular disorders and their consequences (arterial angiopathy, sores);

- Wound healing (ulcers of various etiologies, trophic disorders / sores /, burns, disturbance of wound healing);

- Prevention and treatment of radiation injuries of the skin and mucous membranes with radiation therapy.

Dosage regimen

Solution for injection introducing / a, I / (incl. and as an infusion) and / m.

Depending on the severity of the clinical picture of the initial dose of 10-20 ml / day / in or / and, subsequently administered by 5 ml in / or 5 ml / m daily or several times a week.

When administered in the form of an infusion to 200-300 ml infusion solution (isotonic sodium chloride solution or 5% Dextrose) add 10-20 ml Actovegin^®. The rate of introduction – about 2 ml / min.

At metabolic and vascular disorders of the brain treatment is initiated with daily / in the 10 ml injection for 2 weeks, continue to impose on 5-10 ml / in 3-4 times a week for at least 2 weeks.

At ischemic stroke 20-50 ml diluted in 200-300 ml of infusion solution and administered / drip daily for 1 weeks following injection of 10-20 ml / drip for 2 weeks.

At peripheral (arterial and venous) vascular disorders and their consequences introduced 20-30 ml drug 200 ml infusion solution B / A or / day; about treatment duration 4 weeks.

To wound healing introduced 10 ml in / or 5 ml / m daily or 3-4 twice a week depending on the healing process (in addition to local therapy Actovegin^®).

With the aim of prevention and treatment of radiation injuries of the skin and mucous membranes administered in an average 5 ml / in daily intervals between radiation exposure.

At radiacionnom clean transurethral administered daily 10 ml in combination with antibiotic therapy.

Solution for infusion introduced into / in the drip, or / and by jet 250-500 ml / day. The infusion rate should be about 2 ml / min. The duration of treatment 10-20 infusion.

At metabolic and vascular disorders of the brain at the beginning of treatment administered 250-500 ml / day / in over 2 weeks, further – by 250 ml / in several times a week.

At peripheral vascular disorders and their consequences introduced 250 ml / and or /, daily or several times a week.

To wound healing solution for infusion is administered by 250 ml / in daily or several times per week depending on the rate of wound healing. Perhaps sharing with Actovegin^® in dosage forms for external use.

To prevention and treatment of radiation injuries of the skin and mucous membranes average appoint 250 ml / v per day before and daily during radiotherapy, as well as for 2 Weeks after its completion.

Side effect

Allergic reactions: skin rash, dermahemia, hyperthermia, up to anaphylactic shock.

Contraindications

- Decompensated heart failure;

- Pulmonary edema;

- Oligurija;

- Anurija;

- Fluid retention;

- Hypersensitivity to the drug;

- Hypersensitivity to similar drugs.

FROM caution should be prescribed at hyperchloremia, gipernatriemii.

Pregnancy and lactation

Use of the drug during pregnancy did not have a negative impact on the mother or fetus, However, if you use the drug during pregnancy should take into account the potential risk to the fetus.

Cautions

In connection with the potential development of anaphylactic reactions it is recommended to perform the test (test injection 2 ml / m) before infusion.

In the case of a / m the way to use the drug should be administered slowly in an amount of not more than 5 ml.

Solutions Actovegin^® have a slightly yellowish tint. The color intensity can vary from one batch to another, depending on the characteristics of the raw materials used, however, this does not affect the efficacy and tolerability.

Do not use opaque solution or, containing particles.

After opening the vial or ampoule solution can not be stored.

Overdose

Information on overdose preparations Aktovegin^® not available.

Drug Interactions

Drug Interactions drug Aktovegin^® not installed.

But, in order to avoid possible pharmaceutical incompatibility, do not add other drugs to the infusion solution Actovegin^®.

Conditions of supply of pharmacies

The drug is released under the prescription.

Conditions and terms

The drug should be stored in the dark, inaccessible to children at temperature not exceeding 25 ° C. Shelf life – 5 years.